Todas las investigaciones
Activo, no reclutandoFASE3INTERVENCIONISTA

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

This study is looking at a new gene therapy called delandistrogene moxeparvovec for boys with Duchenne Muscular Dystrophy (DMD). It's designed to see how safe the treatment is and how well it works. Boys who can walk and those who can't will be included. This is a scientific study where some participants will receive the active treatment and others will receive a placebo, which looks like the real thing but has no active medicine. This helps researchers understand the true effects of the new therapy. Everyone in the study will eventually have the chance to receive the actual gene therapy. The study will last for about two and a half years.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE3
Patrocinador
Sarepta Therapeutics, Inc.
Objetivo de inscripción
148
Inicio
31 May 2023
Estimación de finalización
30 Jun 2028

¿De qué trata este estudio?

This study is testing a new gene therapy called delandistrogene moxeparvovec. Gene therapy is a cutting-edge type of treatment that aims to correct the root cause of certain genetic conditions. In the case of Duchenne Muscular Dystrophy (DMD), this new therapy is designed to help the body make a missing protein called dystrophin, which is vital for healthy muscle function.

The study involves boys with DMD, including those who are still able to walk and those who are no longer able to. Researchers want to understand if this new therapy can slow down or stop the progression of the disease and improve muscle strength. They also need to make sure the treatment is safe.

It's important to remember that this is a research study, and while the goal is to find better treatments, there are no guarantees about the results. The study follows strict ethical guidelines to protect the participants.

Puntos clave

  • Tests a new gene therapy (delandistrogene moxeparvovec) for DMD.
  • Includes boys who can and cannot walk.
  • Compares the therapy to a placebo in the first stage.
  • All participants will eventually receive the active therapy.
  • The study lasts for about two and a half years.
  • Careful health checks and muscle tests will be done throughout.

¿Quién puede ser elegible?

To join this study, boys must have been officially diagnosed with Duchenne Muscular Dystrophy (DMD) through medical tests and genetic testing. If they can't walk, they need to meet specific health checks. If they can walk, they need to be between 8 and under 18 years old.

Participants must be able to follow instructions for special muscle tests. They also need to be on a steady dose of steroid medication for at least 12 weeks before starting the study, and this dose shouldn't change much during the study. Boys cannot have certain immune system markers, which will be checked with a blood test. Also, their genetic test results for DMD must show a specific type of change in the DMD gene, but not changes in exon 8 or 9.

Boys cannot have had other gene therapies or experimental treatments for DMD recently. They also can't have other serious medical conditions or abnormal test results that the study doctors think would make participating unsafe. The study doctors will carefully review all these points.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Do you have an official diagnosis of Duchenne Muscular Dystrophy?
  2. Have you been on a steady dose of steroid medicine for at least 12 weeks?
  3. If you can walk, are you between 8 and under 18 years old?
  4. Have you had other gene therapies or experimental DMD treatments recently? (If yes, you might not be eligible.)
  5. Do you have any other serious health conditions that a doctor might think makes this study unsafe for you?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you join this study, you will be in it for about two and a half years (128 weeks). In the first part, some participants will receive the active gene therapy, and others will receive a placebo, which looks like the real treatment but contains no medicine. This is given as a drip into a vein. Neither you, your family, nor your doctors will know whether you received the active treatment or the placebo during this first part.

Throughout the study, you will have regular visits to the clinic. These visits will include checks of your health, blood tests, and special tests to measure your muscle strength and movement. Every participant will eventually have the opportunity to receive the active delandistrogene moxeparvovec gene therapy, either at the beginning of the study or later on.

Riesgos y beneficios potenciales

The potential benefit of joining this study is the chance to receive a new, experimental gene therapy that might help improve muscle function or slow down the progression of DMD. However, as with any new treatment, there are potential risks and side effects that will be explained in detail by the study team. It's crucial to understand that you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (46)

  • Hospital de Niños de Arkansas
    Código postal verificado
    Little Rock, Estados Unidos
  • Lucile Packard Children's Hospital Stanford
    Código postal verificado
    Palo Alto, Estados Unidos
  • University of California at Davis Medical Center
    Código postal verificado
    Sacramento, United States
  • Rady Children's Hospital-San Diego
    Código postal verificado
    San Diego, Estados Unidos
  • University of Florida, UF Health Center for Pediatric Neuromuscular and Rare Diseases
    Código postal verificado
    Gainesville, Estados Unidos
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Código postal verificado
    Chicago, Estados Unidos
  • The Johns Hopkins Hospital, Charlotte R. Bloomberg Children's Center, Pediatric Clinical Research Unit
    Código postal verificado
    Baltimore, Estados Unidos
  • Boston Children's Hospital
    Código postal verificado
    Boston, Estados Unidos
  • Washington University of St. Louis, St. Louis Children's Hospital
    Código postal verificado
    San Luis, Estados Unidos
  • University of Rochester, Department of Neurology
    Código postal verificado
    Rochester, United States
  • Lenox Baker Children's Hospital (Duke University)
    Código postal verificado
    Durham, Estados Unidos
  • Hospital Infantil Nationwide
    Código postal verificado
    Columbus, Estados Unidos

Preguntas comunes

What is Duchenne Muscular Dystrophy?

Duchenne Muscular Dystrophy (DMD) is a genetic condition that causes muscles to become weaker over time.

¿Qué es la terapia génica?

Gene therapy is a new type of treatment that tries to fix the genetic problem that causes a disease, like DMD.

¿Qué es un placebo?

A placebo is a dummy treatment that looks exactly like the real medicine but contains no active ingredients. It helps researchers safely compare the new treatment's effects.

¿Cuánto tiempo durará el estudio?

The study will last for about two and a half years, which is roughly 128 weeks.

Will I or my doctor know if I'm getting the real treatment?

In the first part of the study, neither you, your family, nor your doctors will know if you are receiving the real treatment or the placebo. This is called 'double-blind'.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.